Trusted Resources: Education
Scientific literature and patient education texts
Palliative Care and Symptom Management in Amyloidosis
source: Current Problems in Cancer
year: 2016
authors: Tsukanov J, Fabbro ED
summary/abstract:The World Health Organization definition of palliative care (PC) declares that PC may be incorporated into the management of any patient with a life-limiting illness, whether early in the illness trajectory in conjunction with disease-specific therapies, or at the end of life. This concept of simultaneous care is underscored by an integrated model1 of PC in combination with oncologic care, a model supported by the American Society of Clinical Oncology (ASCO), and an important element of ASCO’s vision for achieving comprehensive cancer care. Light chain amyloidosis (AL), the most common form of systemic amyloidosis, is characterized by the production of light chain proteins by abnormal plasma cells.
The deposition and accumulation of proteins in various organs cause injury and produce symptoms. However, similarly to patients with cancer, symptoms may be because of the disease process or the treatment, and can include fatigue, weakness, dyspnea, pain, dizziness, anorexia, cachexia, edema, diarrhea, and constipation. The degree of symptom burden, timing of onset, and location of affected areas vary among patients and although the initial site of presentation is unpredictable; a dominant site is often identifiable.
organization: Virginia Commonwealth University, USADOI: 10.1016/j.currproblcancer.2016.09.006
read more full text
Related Content
-
FDA Approves Patisiran Infusion for Hereditary Transthyretin-Mediated AmyloidosisThe FDA announced that it has approved p...
-
Immunomodulatory Drugs in AL AmyloidosisImmunoglobulin light chain amyloidosis (...
-
Chafic Karam, MDDr. Chafic Karam is a Neurologist at the...
-
Tegsedi™ to be Available on the NHS for hATTR AmyloidosisAkcea Therapeutics UK Ltd., has announce...
-
At Least Partial Hematological Response After First Cycle of Treatment Predicts Organ Response and Long-term Surviva...AL amyloidosis is a rare plasma cell dys...
-
Case Report: Treatment of Light-Chain Amyloidosis With Daratumumab Monotherapy in Two PatientsImmunoglobulin light-chain amyloidosis (...
-
Renal amyloidosisAmyloidosis is a rare disease caused by ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.